Jaypirca (pirtobrutinib) — Medica
Marginal zone lymphoma (including gastric MALT lymphoma, non-gastric MALT lymphoma, nodal marginal zone lymphoma, splenic marginal zone lymphoma)
Initial criteria
- Patient is age ≥ 18 years
- Patient has tried at least one Bruton tyrosine kinase (BTK) inhibitor (e.g., Calquence, Brukinsa, or Imbruvica)
Approval duration
1 year